DK1196176T3 - Anvendelse af beta-naphthoquinonderivater til fremstilling af lægemidler, der har en hæmmende virkning på hjernens afgivelse af glutamat - Google Patents

Anvendelse af beta-naphthoquinonderivater til fremstilling af lægemidler, der har en hæmmende virkning på hjernens afgivelse af glutamat

Info

Publication number
DK1196176T3
DK1196176T3 DK00958596T DK00958596T DK1196176T3 DK 1196176 T3 DK1196176 T3 DK 1196176T3 DK 00958596 T DK00958596 T DK 00958596T DK 00958596 T DK00958596 T DK 00958596T DK 1196176 T3 DK1196176 T3 DK 1196176T3
Authority
DK
Denmark
Prior art keywords
beta
glutamate
naphthoquinone derivatives
release
inhibitory effect
Prior art date
Application number
DK00958596T
Other languages
English (en)
Other versions
DK1196176T5 (da
Inventor
Maurice Israel
Jordi Molgo
Christian Bloy
Cesar Mattei
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1196176T3 publication Critical patent/DK1196176T3/da
Publication of DK1196176T5 publication Critical patent/DK1196176T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK00958596T 1999-07-21 2000-07-21 Anvendelse af beta-naphthoquinonderivater til fremstilling af lægemidler, der har en hæmmende virkning på hjernens afgivelse af glutamat DK1196176T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9909469A FR2796552A1 (fr) 1999-07-21 1999-07-21 Nouvelle utilisation de derives de la beta-naphtoquinone et de leurs sels pour la fabrication de medicaments exercant un effet inhibiteur sur la liberation de glutamate dans le cerveau
PCT/FR2000/002120 WO2001005404A1 (fr) 1999-07-21 2000-07-21 Utilisation de derives de la beta-naphtoquinone pour la fabrication de medicaments exerçant un effet inhibiteur sur la liberation de glutamate par le cerveau
CA2368850A CA2368850C (en) 1999-07-21 2002-01-22 Methods for the prevention and/or the treatment of glutamate cytotoxicity

Publications (2)

Publication Number Publication Date
DK1196176T3 true DK1196176T3 (da) 2004-06-14
DK1196176T5 DK1196176T5 (da) 2004-07-12

Family

ID=32178092

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00958596T DK1196176T5 (da) 1999-07-21 2000-07-21 Anvendelse af beta-naphthoquinonderivater til fremstilling af lægemidler, der har en hæmmende virkning på hjernens afgivelse af glutamat

Country Status (10)

Country Link
US (4) US7572774B2 (da)
EP (1) EP1196176B1 (da)
AT (1) ATE268599T1 (da)
CA (1) CA2368850C (da)
DE (1) DE60008111T2 (da)
DK (1) DK1196176T5 (da)
ES (1) ES2215716T3 (da)
FR (1) FR2796552A1 (da)
PT (1) PT1196176E (da)
WO (1) WO2001005404A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027325A1 (en) * 1993-05-07 1994-11-24 Vlsi Technology, Inc. Integrated circuit structure and method
EP1961738A1 (en) * 2007-02-15 2008-08-27 Faust Pharmaceuticals New compounds with antiglutamatergic properties and uses thereof
JP2019504116A (ja) 2015-12-16 2019-02-14 クレベクセル ファルマ ナフタゾン又はその塩の１つを含むパルス放出型医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130515A (ja) * 1983-12-15 1985-07-12 Shiratori Seiyaku Kk 血中２，３−ジホスホグリセリン酸上昇剤
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
GB9100028D0 (en) * 1991-01-02 1991-02-20 Ici Plc Compounds
FR2707495B1 (fr) * 1993-07-02 1995-09-01 Roussel Uclaf Nouvelle utilisation de dérivés de la béta-naphtoquinone ainsi que de leurs sels.
BE1011151A3 (fr) * 1997-05-13 1999-05-04 Jose Remacle Utilisation d'une composition pharmaceutique dans le traitement et/ou la prevention de l'ischemie.
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels

Also Published As

Publication number Publication date
DE60008111T2 (de) 2004-12-02
US20070225235A1 (en) 2007-09-27
US20020115617A1 (en) 2002-08-22
PT1196176E (pt) 2004-08-31
DE60008111D1 (de) 2004-03-11
ATE268599T1 (de) 2004-06-15
US20070225236A1 (en) 2007-09-27
DK1196176T5 (da) 2004-07-12
ES2215716T3 (es) 2004-10-16
EP1196176A1 (fr) 2002-04-17
FR2796552A1 (fr) 2001-01-26
WO2001005404A1 (fr) 2001-01-25
US7572774B2 (en) 2009-08-11
CA2368850A1 (en) 2003-07-22
EP1196176B1 (fr) 2004-06-09
CA2368850C (en) 2010-12-07
US20070225237A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
DE69937198D1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
PT1212089E (pt) Combinacao sinergica de roflumilast e salmeterol
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson&#39;s disease or other disorders
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DK1392256T3 (da) Forbedret transdermalt behandlingssystem til behandling af Parkinsons sygdom
DE502005001828D1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
ATE377592T1 (de) Neurotropische substituierte pyrimidine
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MY124786A (en) Bis-arylsulfones
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
DK1196176T5 (da) Anvendelse af beta-naphthoquinonderivater til fremstilling af lægemidler, der har en hæmmende virkning på hjernens afgivelse af glutamat
MXPA02007403A (es) Derivados de pirrol, sustituidos con 4-piridilo y 2,4-pirimidinilo, y su uso en farmacia.
DK1185293T3 (da) IL6RIL6-kimær til behandling af neurodegenerative sygdomme
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
BR0207307A (pt) Inibidores de glyt-1
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system